There are 381 resources available
78TiP - Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase 1/2 ARROS-1 study
Presenter: Benjamin Besse
Session: Poster Display session
83P - Pathologic complete response (pCR) after neoadjuvant (neoadj) chemoimmunotherapy (chemo+IO) in resectable non-small cell lung cancer (NSCLC): A systematic review and pooled analysis
Presenter: Samuel Rosner
Session: Poster Display session
84P - SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: A randomized, double-blind, multicenter, phase 1b/3 trial
Presenter: Yi-Long Wu
Session: Poster Display session
9P - Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC
Presenter: Andrea Ardizzoni
Session: Poster Display session
10P - Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227
Presenter: Solange Peters
Session: Poster Display session
11P - Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Presenter: Matthew Krebs
Session: Poster Display session
12P - A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs
Presenter: Shang-gin Wu
Session: Poster Display session
13P - Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Presenter: Byoung Chul Cho
Session: Poster Display session
14P - Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results
Presenter: Shun Lu
Session: Poster Display session